For many patients with advanced disease or rare conditions, clinical trial enrollment is not just research participation, it is the only available treatment option. Yet fewer than 5% of adult cancer patients historically participate in trials, and 85% of trials fail to recruit enough patients. The gap is structural: 85% of US cancer patients receive care at community hospitals, but most trials run at academic centers. Only 42.4% of US counties have any trial site at all. Expedited programs like FDA Breakthrough Therapy Designation cut late-stage development time by 30%, and the FDA allows over 99% of single-patient expanded access requests to proceed, often within 4 days. But expanded access is not a substitute for enrollment. For sites, the operational challenge is clear: overly restrictive eligibility criteria, protocol amendments (affecting 76% of trials), and geographic concentration all limit patient access. When trials fail to enroll, potentially beneficial therapies remain inaccessible to patients who cannot wait. Improving protocol design, broadening eligibility where evidence supports it, and expanding site networks are not just operational improvements, they are patient access interventions.
Clinical Trials as Treatment Access: What Sites Need to Know
patient accesstrial designenrollment barriers
Clinical Trials as Treatment Access: What Sites Need to Know
How trial design, geography, and regulatory pathways shape patient access to investigational therapies
85%
Trial Recruitment Failure
99%+
FDA Expanded Access
76%
Protocol Amendments
42.4%
County Trial Access
Key Takeaway
Clinical trials are often the only treatment pathway for patients with serious disease, but geographic barriers, restrictive eligibility criteria, and enrollment shortfalls prevent most eligible patients from accessing investigational therapies.